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Abstract
Colorectal cancer (CRC) is the fourth commonest type of malignancy after breast, lung and prostate in the USA and
accounts for approximately 49,190 deaths annually in USA alone. The 5-year survival rate of CRC has increased over
the past decades, in part, due to greater awareness and the widespread implementation of national screening
programmes. Recently, a number of studies reported that males have a higher risk of developing CRC due to the
action of testosterone.
Testosterone is an androgen that is responsible for the development of male secondary sex characteristics and for
spermatogenesis. Studies on rats with mutated Apc tumour-suppressor gene subjected to either ovariectomy or
orchidectomy exhibit different risks of CRC. Female rats subjected to ovariectomy are at higher risk of CRC, whereas
orchidectomised male rats exhibit a lower risk of developing CRC. Sex hormones, in particular estrogen and
testosterone, play a significant role in the development of CRC since the anti-neoplastic effect of estrogen lost
during ovariectomy increases the risk of females developing CRC. Male mice exposed to testosterone after
orchidectomy were also at greater risk than those who were orchidectomised but administered placebo only.
Moreover, the recently established role of membrane androgen receptors in regression of CRC via non-genomic
androgen-dependent action sets these receptors apart from intracellular androgen receptors (iARs) which
themselves promote CRC development. In addition, testosterone-albumin conjugates are selective to membrane
androgen receptors (mARs) and lead to apoptosis via caspase-3 activation. Akt kinases promote invasion of colon
cancer cells when phosphorylated. These kinases are dephosphorylated upon activation of mARs, thereby reducing
colon cancer cell motility and invasiveness.
Testosterone similarly plays important roles in human CRC. Long cytosine-adenine-guanine (CAG) repeats in the
gene for the androgen receptors have been associated with a poor 5-year survival compared to shorter CAG
repeats. Very recently, the measurement of serum unbound testosterone has been suggested as a novel biomarker
along with carcinoembryonic antigen in CRC. In conclusion, testosterone may promote the development of CRC via
a number of pathways, which may place males at greater risk. Testosterone holds promise as a potential biomarker
in CRC risk prediction; however, further studies are required to better define its role in colorectal neoplasia.
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Background
Colorectal cancer (CRC) accounts for an estimated
49,190 deaths annually in the USA and is the fourth
commonest type of malignancy after breast, lung and
prostate. According to the National Cancer Institute, the
prevalence of CRC is highest in the 65–74 age band,
with a median age at diagnosis of 68 years, irrespective
of race and gender. The 5-year relative survival rate of
CRC has increased from 48.6 % in 1975 to 67.2 % in
2008, possibly attributed to increased awareness and the
widespread implementation of CRC screening pro-
grammes [1].
Anatomically, the colorectum refers to the area of the
distal gastrointestinal tract between the caecum and the
rectum. It is anatomically divided into right and left sides.
Clinically, it is divided into proximal to distal, this reflects
the different embryological origins. The proximal colon is
derived embryologically from the midgut and includes the
caecum, ascending colon and proximal two thirds of the
transverse colon. The distal colon is a derivative of the
hindgut and includes the distal third of transverse colon,
descending colon, sigmoid colon and rectum. Of CRC
cases, 90–95 % are sporadic, and their development is de-
scribed using Vogelstein model of carcinogenesis [2]. This
model suggests that there is a transition from normal
mucosa to adenoma initially, followed by the subsequent
development of invasive carcinoma and metastasis due to
sequential accumulation of deleterious mutation in genes
which include APC (adenomatous polyposis coli), K-ras
and p53. Gene inactivation by abnormal methylation
patterns is also implicated in the development of CRC [3].
Approximately 10 % of colorectal cancers arise due germ-
line-inherited mutations. Examples include familial ad-
enomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC). HNPCC arises as
a result of inherited mutations in DNA mismatch repair
genes such as MutL homolog-1 (hMLH1). Defects in
the mismatch repair process leads to repetitive DNA
sequences known as microsatellite instability (MSI)
scattered throughout the genome [4]. The precise aeti-
ology of CRC remains unknown, but certain risk factors
may predispose an individual to CRC including high
consumption of saturated fats and high dietary folic
acid [5]. However, a recent meta-analysis concluded
that no relationship exists between high folic acid
intake and development of CRC [6].
The clinical presentation of CRC varies and depends
on both the location of the primary tumour and the
stage of the disease but may range from altered bowel
habits to melena, with other systemic manifestations
including anorexia and weight loss. Evidence shows that
right-sided CRC is often associated with a poor progno-
sis compared to left-sided CRC, possibly due to the late
clinical presentation seen commonly in right-sided CRC
[7]. This review focuses on the relationship between
testosterone and CRC in males and postmenopausal fe-
males and their risk of developing CRC. It also seeks to
integrate and analyse current knowledge on testosterone
in colorectal neoplasia from the predictive, preventive
and personalised medicine context.
Testosterone and its functions
Classical functions of testosterone
Testosterone is a physiologically important androgen
in both males and females but plays a significant role
in the development of reproductive organs in the
male. It is derived from cholesterol via the classical
pathway, involving production of pregnenolone, 17α-
hydroxyprognenolone and dehydroepiandrosterone.
Testosterone acts via the androgen receptor NR3C4
(nuclear receptor subfamily 3, group C, member 4).
This is a DNA-binding transcription factor which
regulates gene expression and protein synthesis and
plays a central role in increasing intracellular protein
levels. As a result of androgen signalling, tissues pro-
liferate and both basal metabolic demand and energy
consumption increase.
Testosterone is metabolised to estradiol by the action
of aromatase, particularly in females and obese individ-
uals. Testosterone in males is produced mainly by the
smooth endoplasmic reticulum of Leydig cells in the
testes. In females, testosterone is mainly produced by
the ovaries, suprarenal glands and adipose tissue. In the
latter, extraglandular aromatisation of testosterone to
estradiol and androstenedione to estrone occurs [8]. The
anterior pituitary-derived hormones luteinising hor-
mone (LH) and follicle-stimulating hormones (FSHs)
are involved in the complex regulation of testosterone
production and release. Studies have also reported that
low molecular weight signalling molecules such as
nitric oxide (NO) can affect the production of steroids
by Leydig cells. Low concentrations of NO stimulate
steroid production while high concentrations inhibit
their production [9]. In addition, the inhibitory effect
exerted by NO maybe potentiated via inhibition of the
heme-containing steroidogenic enzyme CYP17 [P45oc17].
At higher concentrations of NO, Leydig cell function was
inhibited through CYP11A1 [10]. Moreover, plasma levels
of testosterone are affected by circadian patterns, as levels
peak during sleep. Studies have suggested that hypotestos-
teronism may affect the quality of sleep and that large
doses of exogenous testosterone may contribute to abnor-
mal sleep durations [11]. Testosterone has also been
shown to decrease neuron differentiation in rat embryos.
This action is mediated by the androgen receptor (AR),
which is expressed in large numbers by rat neuron cells;
nonetheless, such findings have not yet been reported in
humans [12]. Testosterone production can be influenced
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by both endogenous and environmental factors. For in-
stance, drugs such as 5-fluorouracil have been reported to
exert toxic effects on the male reproductive system in rats,
resulting in a decreased serum levels of testosterone [13].
Aside from its classical functions as an androgen, the
endogenous production of testosterone is also important
for a healthy cardiovascular system. Numerous studies
have shown that males with low levels of testosterone
were prone to cardiovascular diseases [14, 15]. Further-
more, low levels of endogenous testosterone are directly
linked to male infertility, erectile dysfunction and oligo-
spermia. Conversely, the European Medicine Agency
(EMA) Pharmacovigilance Risk Assessment Committee
have expressed concern at the potential cardiovascular
risks associated with testosterone replacement therapy
[16]. Amos-Landgraf et al. have also demonstrated that
testosterone may promote early colonic adenomagenesis
in rats via as yet unknown mechanisms [17]. The link
between testosterone and CRC development places
males and postmenopausal women at higher risk of
developing CRC and is further discussed in this review.
Non-classical functions of testosterone in Sertoli cells
Testosterone plays an essential role in maintaining sperm-
atogenesis and male fertility. In its absence, spermatogen-
esis is halted at meiosis. Moreover, mature sperm cells
require testosterone in order for them to be released from
the Sertoli cells. The classical actions of testosterone are
widely described in the literature where testosterone acti-
vates gene transcription via translocation of androgen re-
ceptors and binding to specific DNA regulatory element.
AR knock-out mice exhibit infertility since the integ-
rity of the blood-testis barrier (BTB) is compromised,
exposing post-meiotic germ cells to autoimmune attacks
and cytotoxic factors [18]. Moreover, there is also pre-
mature detachment of spermatids from the Sertoli cells
in AR-deficient mice. Studies using Sertoli cells have
confirmed that testosterone activates a number of kinase
signalling pathways, which then alters the expression of
genes that are not dependent on androgen response ele-
ments (AREs) or AR-promoter interactions [19]. These
non-classical signalling pathways lead to the depolarisa-
tion of Sertoli cells by mediating Ca2+ influx via L-type
Ca2+ channels. This results in altered transcriptional
activity, an increase in secretions required by germ cells
and stabilisation of cytoskeletal attachment between
Sertoli cells and the developing germ cells [20]. In
addition, stimulation of Sertoli cells by testosterone re-
sults in activation of a number of kinases and the con-
sequent phosphorylation of CREB transcription factor,
inducing CREB-mediated transcription and ERK kinase
activity, thereby maintaining spermatogenesis. FSH
blocks testosterone-mediated phosphorylation of ERK
via cAMP and protein kinase A (PKA). Nonetheless,
FSH does not inhibit CREB; instead, it induces CREB
phosphorylation by increasing cAMP and PKA in order
to maintain Sertoli cell support and survival of sper-
matocytes [21, 22]. These cells not only supply nutri-
ents to developing germ cells, they are also responsible
for maintaining constant supply of growth factors [23].
The BTB is maintained by testosterone via unknown
mechanisms; this effectively creates a barrier between
the adjacent Sertoli cells separating post-meiotic germ
cells from external environment, therefore supporting
their development [19].
Role of testosterone in colorectal carcinoma
Testosterone and colorectal cancer
The reported incidence of CRC is slightly higher in males
than in females in the USA, and according to Arnold et al.,
the global incidence of CRC is expected to increase by up
to 60 % by 2030 [24, 25]. Recent studies have suggested
that testosterone may promote colorectal adenoma forma-
tion via unknown mechanisms, which may account for
the observed higher male susceptibility to CRC. Mouse
models are widely used to study the function of oncogenes
and to investigate the genetic susceptibility to cancer. A
mouse model of multiple intestinal neoplasia [Min] is gen-
erated by introducing specific mutations in the murine
homolog of adenomatous polyposis coli (Apc) gene using
conditional gene-targeting systems [26–28]. These hetero-
zygous mice carry a truncated Apc gatekeeper tumour-
suppressor gene at exon 15 which is exclusively mutated
in human forms of colorectal adenomas and CRCs [17].
Nonetheless, most of these mice develop tumour primar-
ily in the small intestine but not in the colon. Hence, a
second rat model with a different nonsense mutation in
the rat Apc gene, polyposis in the rat colon (Apc Pirc/+),
was generated which develops adenoma in the colon simi-
lar to that seen in humans. In addition, Pirc male rats are
more susceptible to chemical induction of colorectal tu-
mours with the carcinogen dimethylhydrazine [29]. In an
elegant study by Amos-Landgraf et al., ApcPicr/+ rats were
randomised within litters and were subjected to ovariec-
tomy (OVX), orchidectomy (ORX) or sham control oper-
ation. They were either administered female hormone
replacement [which included medroxyprogesterone acet-
ate (MPA), estradiol (E2) and a combination of MPA and
E2] or male hormone replacement therapy (which in-
cluded dihydrotestosterone) or placebo via slow release
pellets which were implanted subcutaneously in the nape
of the neck. In addition, male mice who underwent ORX
were administered testosterone enanthate in order to sup-
plement the male hormone. Females that underwent OVX
received either female hormone replacement therapy
(HRT) or placebo whereas males received male HRT or
placebo after ORX. As a result, orchidectomised males ad-
ministered with placebo had a lower tumour load, which
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was comparable to that observed in females. In addition,
the tumour load was lower in orchidectomised males in
comparison to orchidectomised males administered with
male HRT. This study demonstrated that male sex hor-
mones, in particular testosterone, may play a role in indu-
cing colonic adenomas. Furthermore, in order to assess
the tumour-promoting role of male sex hormones, an-
other set of mice were injected with the carcinogen azoxy-
methane (AOM) for 6 weeks. After this period, the
investigators showed that male mice were more suscep-
tible to developing adenomas compared to females
injected with AOM [17]. The same male mice were then
either orchidectomised or underwent sham operation and
were administered further AOM injection. Orchidecto-
mised mice developed substantially lower number of ad-
enomas compared to those that underwent sham
operation. A further experiment was carried out on orchi-
dectomised male mice with a set receiving placebo while
other receiving intramuscular injections of testosterone
enanthate. The results confirmed the findings that tes-
tosterone somehow increases the susceptibility of males
developing adenomatous lesions compared to those re-
ceiving only placebo [17].
In contrast to the findings reported in males, female
mice that underwent ovariectomy developed more aden-
omatous lesions compared to those who underwent
sham operations. This may be attributed by the loss of
protective effect by estrogen in ovariectomised females
in suppressing adenomas. The findings reported by
Amos-Landgraf et al. support the notion that female sex
hormones may have protective effects against CRC while
male sex hormones may actively promote CRC develop-
ment [17, 30]. The anti-neoplastic properties of estrogen
have been reported in a number of studies, where the
number of colonic adenomatous lesions was reduced in
ovariectomised female mice administered 17β-estradiol
[31]. Moreover, genetic inactivation of one or both estro-
gen receptors (Er) may contribute to the development of
CRC in females [17]. Nonetheless, contradictory results
have been reported suggesting the strain of mice used
and their underlying genetic susceptibility to carcinogens
may attribute to the differences in results [32, 33].
Testosterone has been shown to exert pro-apoptotic ef-
fects in both prostate and colon cancer cells via a
membrane-initiated mechanism [34]. Dehydroepiandros-
terone (DHEA) can control cell fate, activating nerve
growth factor (NGF) receptors, mainly tropomyosin-
related kinase (Trk)A and p75 neurotrophin receptor in
primary neurons and in PC12 (phaeochromocytoma)
tumour cells. NGF promotes cancer cell proliferation and
apoptosis. Recently, it was shown that DHEA and NGF
strongly blunt serum deprivation-induced apoptosis,
whereas testosterone induces apoptosis of cancer cells,
contrary to findings reported by Amos-Landgraf et al.
[34]. Moreover, the anti-apoptotic effects of both DHEA
and NGF were completely reversed by testosterone. It
appears testosterone is able to block DHEA and NGF
receptors, thereby antagonising their actions [34].
Androgen receptors in CRC signalling
Colon tissues express functional nuclear steroid receptors;
specifically, androgen receptors (ARs), estrogen receptor-
α (ERα) and estrogen receptor-β (ERβ) have been reported
expressed in CRC [35]. ARs are the binding site for
dihydrotestosterone (DHT), and two isoforms of the AR,
androgen receptor A (AR-A) and androgen receptor B
(AR-B) [110 kDa], were reported by Catalano et al. [36].
Both of these were detected in healthy colonic mucosa
whereas only AR-A (an 87-kDa isoform) was detected in
neoplastic colonic mucosa. Neoplastic colonic mucosa is
characterised by loss of expression of the AR-B isoform,
whereas AR-A expression is maintained [36]. Low levels
of AR-A are normally detected in the fetal colon, whereas
AR-B is expressed in both the fetal and adult colons. How-
ever, the expression of AR-A in CRC may be indicative of
loss of cell differentiation [36]. Recently, it was reported
that membrane androgen receptors (mARs) expressed in
colonic tumours may trigger apoptosis in neoplastic cells.
mARs are cell-surface G-protein coupled receptors
(GPCR) which signal via modulation of intracellular
calcium or inositol 1,4-5-triphosphate second messenger
pathways. The non-genomic androgen-dependent action
of these mARs sets them apart from the intracellular
androgen receptors (iARs) which mediate signalling
through dimerisation, nuclear translocation and activation
of androgen-specific target genes [37]. Membrane andro-
gen receptors may induce tumour regression, in contrast
to iARs according to Gu et al. [38]. Colon cancer tissues
isolated from mice xenograft tumours and two colon
cancer cell lines (Caco2 and HCT116 cells) were used in
this study by Gu et al. Significant mAR expression were
reported in xenograft tumour tissues and cell lines com-
pared to healthy or non-transformed cells. Furthermore,
when human epithelial colorectal adenocarcinoma cells
(Caco2 cells) were incubated with either radiolabeled
testosterone, varying concentrations of DHT or estradiol,
the radiolabeled testosterone was displaced by DHT.
These radioligand binding studies suggest high affinity
and selectivity of mARs towards specific androgens [39].
Furthermore, fluorescence staining of Caco2 and
HCT116 cells treated with testosterone-3-[O-carboxy-
methyl] oxime human serum albumin (testosterone-
HSA) for 24 h revealed evidence of apoptosis via
caspase-3 activation. These reported effects were solely
attributed to the activation of mAR expressed in colon
cancer cells. As mARs are not expressed in non-
neoplastic colon cells, these do not respond to testos-
terone treatment compared to colon cancer cells. No
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iARs were detected in membrane preparations of colon
cancer cells nor were involved in any part of the study
by Gu et al. The study concluded that colonic tumour
cells may over-express pro-apoptotic pathways in an
mAR-dependent fashion leading to tumour regression and
that mARs may present novel pathways for pharmacologic
therapy in colorectal neoplasms [39].
Aside from mAR expression, protein kinase B (Akt) is a
serine/threonine-specific protein kinase which plays a
major role in the invasiveness of colon cancer cells in
response to a variety of stimuli ranging from heregulin,
PAK1 and Sprouty-2 [40–42]. Phosphorylated Akt (p-Akt)
is upregulated in colonic tumour cells but not in non-
transformed cells, and is dephosphorylated following
long-term mAR activation with testosterone-albumin con-
jugate (TAC) treatment both in vitro and in vivo [38]. As
a result, the upstream regulator of Akt, in particular PI-
3K, is dephosphorylated upon long-term TAC treatment,
thereby reducing cell motility in colon cancer and its inva-
siveness. In addition, control experiments using colon
tumour cells treated with either testosterone or HSA
alone show that this does not downregulate p-Akt when
compared to testosterone-HSA treatment. This appar-
ent contraindication is in line with the dual role of
testosterone in simultaneous binding of mARs [thereby
inducing p-Akt downregulation] and iARs [thereby
inducing p-Akt upregulation] within the same cells.
Vinculin, a cytoskeletal protein which links integrin
adhesion molecules to actin, was reported as the main
target of mAR activation that may regulate cell motility
since inhibition of vinculin via phosphorylation pro-
motes colonic cancer cell migration [38].
Length of cytosine-adenine-guanine repeats in androgen
receptor gene and CRC
CRC is known to develop through a number of genetic
mechanisms, which include microsatellite instability and
suppression of APC gene activity. The growth of cells in
colonic mucosa is in part regulated by androgens includ-
ing testosterone. The gene encoding the AR is located
on chromosome Xq11-12 and contains varying number
of CAG repeats (8-35 CAG repeats) in normal popula-
tions. These CAG can alter the function of the AR gene.
A case-control study investigating the effect of this poly-
morphism on CRC risk was carried out on 550 CRC
cases and 540 healthy controls, who were analysed for
presence of CAG sequences in the AR gene using poly-
merase chain reaction (PCR) [43]. The study showed
that the CRC group had a longer CAG repeat length
compared to the control group and that this repeat con-
fers an increased risk of developing CRC in both males
and females, whereas a shorter CAG repeat size may
protect individuals against CRC. In addition, differences
in CAG repeat may determine the survival rate in CRC.
Cases with long CAG repeat sequences had a poor 5-
year survival compared to those with shorter CAG re-
peats. In addition, the absence of AR expression in long
CAG repeat sequences was associated with tumour size
larger than 5 cm in diameter, which were moderate to
poorly differentiated (at T3–T4 and N1–2 stages) com-
pared to those with normal expression of AR and short
CAG repeat sequences. Aside from the link to tumour
stage, these patients were also reported to have a poor sur-
vival rate even after postoperative adjuvant chemotherapy
as they demonstrated greater risk of recurrence or metas-
tasis [43]. On the contrary, a different study has reported
that there is no association between the length of CAG re-
peats in the AR and colorectal cancer. Similarly, the CAG
repeat in the AR showed no association with the overall
survival rate. Instead, an association between the estrogen
receptor 2 (ESR2) CAG repeat polymorphism was re-
ported to be associated with increased risk of CRC among
women but not men [44].
A further study investigating the role of the ESR2
CAG repeat reported a sixfold increased risk of CRC
in women harbouring two ESR2 short alleles [less
than 22 repeats] compared to women harbouring two
long alleles (more than 22 repeats) [45]. Aside from
CAG repeats, co-activator-associated arginine methyl-
transferase 1 (CARM1), a protein with arginine-specific
histone methyltransferase activity, has been reported to
promote nuclear receptor activity and act as a molecular
switch that controls gene-specific transcription factors
including p53, NF-ĸB, LEF1/TCF4 and E2Fs. It primarily
binds to the histone and p160 co-activators in order to
activate nuclear receptors which includes ARs [46, 47]. In
doing so, CARM1 plays a significant role in cell prolifera-
tion and survival [48, 49]. Overexpression of CARM1 in
CRC was reported in CRC specimens but was weakly
expressed in normal mucosal cells. Furthermore, CARM1
is believed to modulate transcription of p53, a tumour-
suppressor gene, as well as of NF-ĸB. CARM1 inhibits the
p53 response and promoted the NF-ĸB response in Caco2
cells via unknown mechanisms [50]. More molecular and
genetic profiling of CRC is required to identify the precise
role of these proteins.
Sex hormones and gender differences in CRC
Age is one of the strongest risk factors for the develop-
ment of CRC, with 90 % of cases reported in individuals
over the age of 50. However, the incidence of CRC is
lower in women across all age groups [51]. Female sex
hormones are known to have a protective role against
the development of a number of diseases, including
cardiovascular disease (CVD) as well as CRC according
to the Woman’s Health Initiative (WHI) study [17]. A
recent randomised controlled trial in women on hor-
mone replacement therapy over a period of 5 years
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showed a substantial reduction in CRC in women on
equine estrogen (E2) and medroxyprogesterone acetate
(MPA) compared to placebo [52]. Following this clinical
trial, a subsequent investigation was conducted in fe-
males who had previously undergone hysterectomy and
were administered E2 only. Surprisingly, the second trial
showed that women administered E2 were not protected
against the development of CRC. This suggests that MPA,
in particular progestin, may play a protective role in fe-
males [53]. Nonetheless, the precise mechanism is un-
known and requires further investigations. The hormonal
differences in different genders do not end there since a
number of studies have shown that female patients re-
spond better than male patients to adjuvant chemotherapy
in a number of cancers. These observations suggest that
gender and hormones play a central role in the develop-
ment of CRC and its prognosis.
Female sex hormones confer a protective effect against
CRC development. Estrogen is a member of the steroid
hormone family and is usually associated with female re-
productive function. 17β-estradiol (E2) is the most potent
estrogen in humans when compared to estrone (E1) and
estriol (E3). Estrogen functions are mediated by two nu-
clear receptor subtypes, estrogen receptor α (ERα) and es-
trogen receptor β (ERβ), which then bind to genomic
regulatory regions known as estrogen response element
(ESR) either as a homodimer or heterodimer. This then
results in transcription and activation of a number of genes
(VEGF, TGF-β, cadherins, laminins) which are involved in
angiogenesis, cell adhesion and apoptosis. Non-genomic
effects of estrogen are independent of DNA interactions;
instead, it modulates cellular processes via activation of
diverse intracellular pathways including protein kinase C
(PKC), intracellular Ca2+, cytosolic cAMP, NO and MAPK
[51]. ERβ is considered to confer the protective effects of
estrogen against CRC as they are primarily found in nor-
mal colonic epithelium and their expression declines in
CRC cells [54, 55]. Moreover, colorectal cells and even
cancer epithelial cells do not co-express ERα and ERβ.
Studies have shown ERβ expression results in inhibition of
proliferation and G1 phase cell-cycle arrest [56]. Moreover,
ERβ inhibits cMyc and tumour growth in a mouse model,
suggesting ERβ may have anti-proliferative properties
which are not seen with ERα [57]. Nonetheless, the exact
role of estrogen and ERs in CRC is still unknown and some
studies have suggested that menopausal women may have
a higher risk of CRC due to lower levels of estrogen, as well
as due to loss of cell cycle regulatory effects of ERβ. This is
evidenced by studies which show that the use of oral con-
traceptives and HRT treatment in postmenopausal female
translates to lower reported incidences in CRC [51]. Trials
carried out by the WHI study in females administered with
estrogen in combination with progestin reported a 40 %
lower risk of CRC compared to those on placebo [52].
On the other hand, males having lower androgenicity
as a result of longer CAG repeats in the AR gene or on
treatment with androgen deprivation therapy were asso-
ciated with a high reported incidence of CRC. Thus, the
protective effects of estrogen and progesterone in
women and testosterone in men against CRC is clinically
important. Studies have shown that males tend to de-
velop colonic lesions at an earlier age compared to fe-
males who often develop neoplastic changes at much
later stages in life [58]. Moreover, males on androgen
deprivation therapy with gonadotropin-releasing hor-
mone (GnRH) agonists for prostate cancer treatment
have an increased risk of CRC. Furthermore, males who
underwent orchiectomies were reported to have higher
incidences of CRC followed by those on GnRH agonist
therapy especially if they are on androgen deprivation
treatment for a long period of time [59]. The results
from these studies suggest that testosterone confers
some degree of protection against CRC and contradicts
other investigations which suggest that testosterone may
promote CRC [17, 34, 60]. In addition, high levels of
testosterone have been associated with an increased risk
of early death after cancer diagnosis in both males and
females, but such findings have not been reported in CRC
[61]. Males with higher levels of testosterone and sex
hormone-binding globulin (SHBG) but low levels of estra-
diol were shown to have a lower risk of developing CRC.
This suggests that males with lower androgenicity due to
reduce AR activity or low circulating androgens were at
greater risk of CRC; the risk is greater in males undergo-
ing androgen deprivation therapy [59]. Moreover, obese
males, particularly those with a higher ratio of estradiol to
testosterone, have an increased activity of aromatase that
therefore may predispose these individuals to CRC. Estra-
diol relays negative feedback response which inhibits
secretion of LH and subsequently testosterone release
[62]. Therefore, contrary to females, it can be concluded
that estradiol confers no protection against CRC in males.
Premenopausal females normally have a higher ratio of
estradiol to testosterone levels as a result of higher aroma-
tase activity leading to increased production of estradiol.
This therefore leads to a lower risk of developing CRC in
females when compared to males [63]. Aromatase activity
also offers protective effects in postmenopausal females by
increasing the ratio of estradiol to testosterone, but levels
of estradiol are not as high as those seen in premeno-
pausal females. Nevertheless, these aromatase-dependent
beneficial effects on CRC risk are only observed in non-
obese females but not in obese females [63].
Testosterone as a tumour marker in CRC
Hypotestosteronemia—defined as low levels of testoster-
one (11 nmol/L or 320 ng/dL)—has been reported to be
a contributing factor in the development of CRC [64].
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This makes quantification of serum testosterone an at-
tractive potential biomarker for prediction of CRC risk.
A study by Holland et al. evaluated concentration of tes-
tosterone in patients with histologically confirmed CRC.
They quantified serum testosterone, estradiol and carci-
noembryogenic antigen (CEA) in CRC patients before
and after undergoing surgical resection. The results were
then compared with the control group who were carry-
ing the benign gastrointestinal pathologies. Their results
showed that unbound serum testosterone was lower in
those with colon or rectal neoplasia and 56.9 % of CRC
cases had elevated CEA levels [65]. The combined use of
both of these biomarkers increased the sensitivity of
tumour screening compared to the use of CEA in iso-
lation. The authors concluded that quantification of
testosterone in combination with CEA may enhance
tumour screening and suggested that it could be used
for diagnosis and follow-up of CRC, especially in CRC
patients with normal CEA [65]. Hypogonadal males
with high levels of prolactin might be at a greater risk
of CRC since prolactin is reported to exert mitogenic
effects which may confer to tumorogenecity. Hence,
prolactin in conjunction with testosterone may be a
useful tumour marker in CRC [66]. Serum testosterone
is already in clinical use as a biomarker for prostate
cancer and has been proposed as a tool for measuring
prognosis of breast cancer in postmenopausal women
[67]. Nonetheless, data of its use in CRC is limited and
emerging evidences on the role which testosterone
plays in CRC warrants further long-term double-
blinded clinical trials.
Testosterone and CRC—from biology to predictive and
personalised medicine
The experimental, epidemiological and clinical studies
outlined earlier in this review provide compelling evidence
that androgens are involved in the process of CRC devel-
opment. Although CRC is not a hormone-dependent
cancer in the classical sense, the role of sex hormones in
its pathogenesis has potential translational applications in
pre-symptomatic diagnosis, risk stratification and treat-
ment. The implications of this body of knowledge are ex-
tensive, particularly in the light of shifting trends towards
predictive, preventive and personalised medicine (PPPM)
in oncology. The ultimate aim of PPPM in cancer is to im-
prove patient outcome through the implementation of
rapid, sensitive and specific new methods for tumour
detection [68]. This requires the development and valid-
ation of predictive and prognostic biomarkers to guide
diagnosis and therapy. Current screening and diagnostic
protocols for CRC are based on colonoscopy, biopsy and
histologic examination of tissue samples. Furthermore,
CRC is nearly asymptomatic in its earliest stages. This
combined scenario of asymptomatic early disease and
invasive diagnostic procedures reinforces the need for the
development of novel biomarkers to facilitate screening
and the identification of individuals at risk. A detailed
overview of existing and emerging molecular biomarkers
of CRC is available in the literature and is beyond the
scope of this review [69].
The quantification of serum testosterone as an adjunct
to existing biomarkers for CRC is an attractive prospect.
The availability of direct automated chemiluminescent
assays for multipurpose immunoassay platforms facili-
tates measurement of testosterone in routine clinical
chemistry laboratories, rendering the process rapid and
convenient. However, some authorities have been highly
critical of the accuracy and precision of routine immuno-
assays when compared to gold-standard liquid chromatog-
raphy/tandem mass spectrometry (LC/MSMS) platforms
[70]. Wang et al. showed that routine immunoassays
should not be used to measure testosterone in the normal
female or paediatric ranges [71]. Similarly, Moal et al.
showed that no immunoassay is reliable when low testos-
terone concentrations (≤3.47 nmol/L) are measured [72].
The controversial nature of this issue dictates the burgeon-
ing need to better define the sensitivity of existing assays,
inform clinicians of the implications of these limitations
and implement the use of gold-standard platforms to
improve sensitivity and accuracy.
The determination of androgen receptor CAG repeat
length provides a second aspect of testosterone physiology
that has potential translational application in the biomarker
arena. Clearly, genotypes are attractive as disease bio-
markers. They are independent of age and do not change,
and technological advances allow for high-throughput
multiplex genotyping assays that provide high fidelity and
reproducibility. Furthermore, the potential integration of
genotype-based data into a risk-prediction or prognosis-
prediction algorithm for CRC lays the foundation for a
personalised therapeutic approach addressed to a particular
patient.
One of the key expert recommendations by the EPMA
(European Association for Predictive, Preventive and
Personalised Medicine) concerning cancer biomarkers
provides a stark reminder of the complex mechanisms at
play in cancer biology. The authors emphasise the point
that cancer is a multifactorial, whole-body disease that
leads to alterations in multiple cell pathways. Hence, a
paradigm shift is required, moving from a traditional
single-factor strategy to a multi-parameter approach
[73]. When considering testosterone as a potential bio-
marker in CRC, this approach is highly relevant, as diag-
nostic or prognostic benefit might be obtained if
testosterone levels or CAG repeat length are considered
in combination with data from other biomarkers. This
requires the development and validation of biomarker
panels to provide meaningful data in risk prediction or
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stratification. However, one of the major challenges
facing cancer biomarker development is the integration
of large ‘omics’ datasets with clinical data and their
subsequent interpretation and translational application.
Clearly, the bench-to-bedside translation of multi-
parameter biomarker panels remains a major hurdle and
accounts for the significant discrepancy in numbers
between the number of biomarkers in pre-clinical devel-
opment and biomarkers in commercial use [74].
Conclusions
CRC is one of the most common types of cancer with
higher prevalence in those above the age of 50 [51]. The
5-year survival rate of CRC has improved over the years
as a result of international awareness and better screening
programmes. Testosterone as a male androgen respon-
sible for the development of secondary sex characteristics
as well as spermatogenesis has recently been reported to
increase susceptibility of acquiring CRC in males. Such
findings were supported by animal studies which con-
cluded that orchidectomised mice have a lower risk of
developing CRC compared to controls. On contrary,
female mice who underwent ovarectomy were at a greater
risk of developing CRC than their counterparts who had
no ovarectomy [17]. These findings support the notion
that sex hormones may confer protection against CRC or
promote the development of CRC as the case with testos-
terone. Moreover, the recently discovered mARs are
significant, since activation of these receptors occurs
predominately in CRC but not in normal colonic mucosa.
In addition, activation of these receptors by testosterone-
HSA conjugates triggers apoptotic pathways that offer
protection against CRC.
Tumour invasiveness is determined by Akt, a serine
kinase which regulates the motility of colonic cancer
cells and prevents their invasiveness [75]. The activities
of these kinases are enhanced by testosterone-HSA,
thereby inhibiting tumour invasion and distant spread.
Aside from Akt kinases, the length of CAG repeats in
the AR gene is equally important since long CAG
repeats were associated with poor 5-year survival com-
pared to short CAG repeats. Apart from the CAG
tandem repeats, the CARM1 protein is important in cell
proliferation and survival [50]. Overexpression of these
proteins have been reported in CRC specimens, but their
precise role and mechanisms are yet to be determined.
Other non-modifiable factors such as gender differ-
ences and different functions of sex hormones may
explain why CRC cases are often reported in males. Fe-
males are often protected against CRC due to anti-
cancer properties of estrogen and activity of aromatase
which converts testosterone to estrogen. As a result,
CRC cases are often presented much later in postmeno-
pausal females compare to males [63]. The precise role
of testosterone in CRC is not well understood, and a
number of conflicting studies have been published on
the relation between testosterone and CRC risk. There-
fore, more long-term clinical trials, molecular and
genetic studies are required in order to determine the
precise role of testosterone in human colonic mucosa
since most experimental data currently available is on
animal models which may not full represent normal
human pathophysiology. Recently, testosterone was pro-
posed as a tumour biomarker for CRC in conjunction
with other tumour markers currently available such as
CEA. In doing so, it may increase the specificity of these
tumour markers to allow better follow-up after surgical
management of CRC. Despite the biological link between
testosterone and CRC, the translational application of
this knowledge into patient care requires further re-
search. In particular, the use of testosterone as a cancer
biomarker requires harmonisation of laboratory quantifi-
cation methods to overcome issues of sensitivity and ac-
curacy. Furthermore, diagnostic and prognostic models
involving multiple biomarkers need to be developed and
validated in different populations to determine whether
testosterone has any clinical utility in CRC. The develop-
ment of novel biomarkers for CRC should in part be
based on sound biological knowledge about the in vivo
function of the chosen molecules, and this requires bet-
ter understanding of the cell pathways that are dysregu-
lated in the development of colorectal neoplasia. CRC is
a multifactorial disease that is affected by a multitude of
risk factors, including the environmental exposure to
chemicals, toxins and carcinogens, as well as dietary
supplements. Therefore, a wider clinical picture should
be obtained using data extrapolated from molecular
studies and animal models in order to better determine
the precise mechanism that drives CRCs.
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